Review



shrna plasmid with pspax2  (Addgene inc)


Bioz Verified Symbol Addgene inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 98

    Structured Review

    Addgene inc shrna plasmid with pspax2
    Shrna Plasmid With Pspax2, supplied by Addgene inc, used in various techniques. Bioz Stars score: 98/100, based on 14383 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/shrna+plasmid+with+pspax2/pmc13050104-51-9-13?v=Addgene+inc
    Average 98 stars, based on 14383 article reviews
    shrna plasmid with pspax2 - by Bioz Stars, 2026-07
    98/100 stars

    Images



    Similar Products

    98
    Addgene inc shrna plasmid with pspax2
    Shrna Plasmid With Pspax2, supplied by Addgene inc, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/shrna+plasmid+with+pspax2/pmc13050104-51-9-13?v=Addgene+inc
    Average 98 stars, based on 1 article reviews
    shrna plasmid with pspax2 - by Bioz Stars, 2026-07
    98/100 stars
      Buy from Supplier

    98
    Addgene inc shrna plasmid plvx dpep2 puro plasmid
    Shrna Plasmid Plvx Dpep2 Puro Plasmid, supplied by Addgene inc, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/shrna+plasmid+with+pspax2/pm41803155-359-10-19?v=Addgene+inc
    Average 98 stars, based on 1 article reviews
    shrna plasmid plvx dpep2 puro plasmid - by Bioz Stars, 2026-07
    98/100 stars
      Buy from Supplier

    98
    Addgene inc shrna lentivirus vector
    a Enrichment of EMT and NE gene signatures following EIF6 knockdown in non-NE cell states. RNA-seq analysis is performed in n = 2 biologically independent samples. b Gene expression profiling of EMT- and NE-associated pathways upon EIF6 knockdown in non-NE cell states. RNA-seq analysis is performed in n = 2 biologically independent samples. c Immunoblot analysis of EMT-associated and NE proteins following EIF6 knockdown across multiple SCLC models. Blots are representative of n = 3 biologically independent experiments. For H69M, the samples derive from the same experiment but different gels for ZEB1, another for ZEB2, another for MYCN, another for YAP1, another for eIF6 and c-Myc, another for ASCL1, NEUROD1 and β-tubulin were processed in parallel; For H82R, the samples derive from the same experiment but different gels for ZEB2, ZEB1, MYCN and c-Myc, another for YAP1 and ASCL1, another for NEUROD1, eIF6 and β-tubulin were processed in parallel. For H209A, the samples derive from the same experiment, but different gels for ZEB2, ZEB1, MYCN and c-Myc, another for YAP1 and ASCL1, another for eIF6, another for NEUROD1 and β-tubulin were processed in parallel. d H69 cells with EIF6 knockdown were treated with HGF (40 ng mL⁻¹) for two weeks. Bright-field images show adherent growth (top). Attached colonies were stained with crystal violet for quantification ( n = 3 biologically independent experiments). Scale bar, 100 μm. Error bars represent s.d. Statistical significance was assessed using a two-sided unpaired Wilcoxon rank-sum test. e Re-expression of <t>shRNA-resistant</t> wild-type EIF6 using pCDH <t>lentivirus</t> restores HGF-induced cell attachment in EIF6 knockdown cells. Top: immunoblot showing EIF6 knockdown and re-expression efficiency. Bottom, quantification of crystal violet–stained colonies ( n = 4 independent experiments). Error bars represent s.d. Statistical significance was assessed using a two-sided unpaired Wilcoxon rank-sum test. f Representative images of H69 cells with EIF6 knockdown and re-expression after HGF treatment (40 ng mL⁻¹) for three weeks. Bright-field images (left) and crystal violet–stained colonies (right) are shown. Scale bar, 20 μm. g Live/dead cell analysis of shNTC and shEIF6 H69M cells treated with or without EP (carboplatin 10 μM and etoposide 2 μM) for 72 h, measured by flow cytometry. Data are mean ± SEM from n = 3 independent experiments. Statistical significance was determined using a two-sided unpaired Wilcoxon rank-sum test. h Chemotherapy sensitivity of subcutaneous xenografts derived from shNTC or shEIF6 H69 cells. Tumour volume changes were assessed after three chemotherapy cycles ( n = 13 tumours per group). Response categories were defined as CR (−100%), PR (−30% to 0%) and PD (>20%). Lowercase letters indicate tumours used for immunohistochemistry in i . Created in BioRender. Shen, S. (2026) https://BioRender.com/5p1ea8h . i Representative immunohistochemistry images of ASCL1, NEUROD1, POU2F3, YAP1 and EIF6 in corresponding tumours from h . Scale bars, 50 μm.
    Shrna Lentivirus Vector, supplied by Addgene inc, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/shrna+plasmid+with+pspax2/pmc12946193-514-7-15?v=Addgene+inc
    Average 98 stars, based on 1 article reviews
    shrna lentivirus vector - by Bioz Stars, 2026-07
    98/100 stars
      Buy from Supplier

    98
    Addgene inc shrna constructs with pspax2
    a Enrichment of EMT and NE gene signatures following EIF6 knockdown in non-NE cell states. RNA-seq analysis is performed in n = 2 biologically independent samples. b Gene expression profiling of EMT- and NE-associated pathways upon EIF6 knockdown in non-NE cell states. RNA-seq analysis is performed in n = 2 biologically independent samples. c Immunoblot analysis of EMT-associated and NE proteins following EIF6 knockdown across multiple SCLC models. Blots are representative of n = 3 biologically independent experiments. For H69M, the samples derive from the same experiment but different gels for ZEB1, another for ZEB2, another for MYCN, another for YAP1, another for eIF6 and c-Myc, another for ASCL1, NEUROD1 and β-tubulin were processed in parallel; For H82R, the samples derive from the same experiment but different gels for ZEB2, ZEB1, MYCN and c-Myc, another for YAP1 and ASCL1, another for NEUROD1, eIF6 and β-tubulin were processed in parallel. For H209A, the samples derive from the same experiment, but different gels for ZEB2, ZEB1, MYCN and c-Myc, another for YAP1 and ASCL1, another for eIF6, another for NEUROD1 and β-tubulin were processed in parallel. d H69 cells with EIF6 knockdown were treated with HGF (40 ng mL⁻¹) for two weeks. Bright-field images show adherent growth (top). Attached colonies were stained with crystal violet for quantification ( n = 3 biologically independent experiments). Scale bar, 100 μm. Error bars represent s.d. Statistical significance was assessed using a two-sided unpaired Wilcoxon rank-sum test. e Re-expression of <t>shRNA-resistant</t> wild-type EIF6 using pCDH <t>lentivirus</t> restores HGF-induced cell attachment in EIF6 knockdown cells. Top: immunoblot showing EIF6 knockdown and re-expression efficiency. Bottom, quantification of crystal violet–stained colonies ( n = 4 independent experiments). Error bars represent s.d. Statistical significance was assessed using a two-sided unpaired Wilcoxon rank-sum test. f Representative images of H69 cells with EIF6 knockdown and re-expression after HGF treatment (40 ng mL⁻¹) for three weeks. Bright-field images (left) and crystal violet–stained colonies (right) are shown. Scale bar, 20 μm. g Live/dead cell analysis of shNTC and shEIF6 H69M cells treated with or without EP (carboplatin 10 μM and etoposide 2 μM) for 72 h, measured by flow cytometry. Data are mean ± SEM from n = 3 independent experiments. Statistical significance was determined using a two-sided unpaired Wilcoxon rank-sum test. h Chemotherapy sensitivity of subcutaneous xenografts derived from shNTC or shEIF6 H69 cells. Tumour volume changes were assessed after three chemotherapy cycles ( n = 13 tumours per group). Response categories were defined as CR (−100%), PR (−30% to 0%) and PD (>20%). Lowercase letters indicate tumours used for immunohistochemistry in i . Created in BioRender. Shen, S. (2026) https://BioRender.com/5p1ea8h . i Representative immunohistochemistry images of ASCL1, NEUROD1, POU2F3, YAP1 and EIF6 in corresponding tumours from h . Scale bars, 50 μm.
    Shrna Constructs With Pspax2, supplied by Addgene inc, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/shrna+plasmid+with+pspax2/pm41565695-281-10-14?v=Addgene+inc
    Average 98 stars, based on 1 article reviews
    shrna constructs with pspax2 - by Bioz Stars, 2026-07
    98/100 stars
      Buy from Supplier

    98
    Addgene inc plko 2 shrna plasmid
    a Enrichment of EMT and NE gene signatures following EIF6 knockdown in non-NE cell states. RNA-seq analysis is performed in n = 2 biologically independent samples. b Gene expression profiling of EMT- and NE-associated pathways upon EIF6 knockdown in non-NE cell states. RNA-seq analysis is performed in n = 2 biologically independent samples. c Immunoblot analysis of EMT-associated and NE proteins following EIF6 knockdown across multiple SCLC models. Blots are representative of n = 3 biologically independent experiments. For H69M, the samples derive from the same experiment but different gels for ZEB1, another for ZEB2, another for MYCN, another for YAP1, another for eIF6 and c-Myc, another for ASCL1, NEUROD1 and β-tubulin were processed in parallel; For H82R, the samples derive from the same experiment but different gels for ZEB2, ZEB1, MYCN and c-Myc, another for YAP1 and ASCL1, another for NEUROD1, eIF6 and β-tubulin were processed in parallel. For H209A, the samples derive from the same experiment, but different gels for ZEB2, ZEB1, MYCN and c-Myc, another for YAP1 and ASCL1, another for eIF6, another for NEUROD1 and β-tubulin were processed in parallel. d H69 cells with EIF6 knockdown were treated with HGF (40 ng mL⁻¹) for two weeks. Bright-field images show adherent growth (top). Attached colonies were stained with crystal violet for quantification ( n = 3 biologically independent experiments). Scale bar, 100 μm. Error bars represent s.d. Statistical significance was assessed using a two-sided unpaired Wilcoxon rank-sum test. e Re-expression of <t>shRNA-resistant</t> wild-type EIF6 using pCDH <t>lentivirus</t> restores HGF-induced cell attachment in EIF6 knockdown cells. Top: immunoblot showing EIF6 knockdown and re-expression efficiency. Bottom, quantification of crystal violet–stained colonies ( n = 4 independent experiments). Error bars represent s.d. Statistical significance was assessed using a two-sided unpaired Wilcoxon rank-sum test. f Representative images of H69 cells with EIF6 knockdown and re-expression after HGF treatment (40 ng mL⁻¹) for three weeks. Bright-field images (left) and crystal violet–stained colonies (right) are shown. Scale bar, 20 μm. g Live/dead cell analysis of shNTC and shEIF6 H69M cells treated with or without EP (carboplatin 10 μM and etoposide 2 μM) for 72 h, measured by flow cytometry. Data are mean ± SEM from n = 3 independent experiments. Statistical significance was determined using a two-sided unpaired Wilcoxon rank-sum test. h Chemotherapy sensitivity of subcutaneous xenografts derived from shNTC or shEIF6 H69 cells. Tumour volume changes were assessed after three chemotherapy cycles ( n = 13 tumours per group). Response categories were defined as CR (−100%), PR (−30% to 0%) and PD (>20%). Lowercase letters indicate tumours used for immunohistochemistry in i . Created in BioRender. Shen, S. (2026) https://BioRender.com/5p1ea8h . i Representative immunohistochemistry images of ASCL1, NEUROD1, POU2F3, YAP1 and EIF6 in corresponding tumours from h . Scale bars, 50 μm.
    Plko 2 Shrna Plasmid, supplied by Addgene inc, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/shrna+plasmid+with+pspax2/pm41150682-353-13-17?v=Addgene+inc
    Average 98 stars, based on 1 article reviews
    plko 2 shrna plasmid - by Bioz Stars, 2026-07
    98/100 stars
      Buy from Supplier

    98
    Addgene inc plko 1 shrna plasmids
    a Enrichment of EMT and NE gene signatures following EIF6 knockdown in non-NE cell states. RNA-seq analysis is performed in n = 2 biologically independent samples. b Gene expression profiling of EMT- and NE-associated pathways upon EIF6 knockdown in non-NE cell states. RNA-seq analysis is performed in n = 2 biologically independent samples. c Immunoblot analysis of EMT-associated and NE proteins following EIF6 knockdown across multiple SCLC models. Blots are representative of n = 3 biologically independent experiments. For H69M, the samples derive from the same experiment but different gels for ZEB1, another for ZEB2, another for MYCN, another for YAP1, another for eIF6 and c-Myc, another for ASCL1, NEUROD1 and β-tubulin were processed in parallel; For H82R, the samples derive from the same experiment but different gels for ZEB2, ZEB1, MYCN and c-Myc, another for YAP1 and ASCL1, another for NEUROD1, eIF6 and β-tubulin were processed in parallel. For H209A, the samples derive from the same experiment, but different gels for ZEB2, ZEB1, MYCN and c-Myc, another for YAP1 and ASCL1, another for eIF6, another for NEUROD1 and β-tubulin were processed in parallel. d H69 cells with EIF6 knockdown were treated with HGF (40 ng mL⁻¹) for two weeks. Bright-field images show adherent growth (top). Attached colonies were stained with crystal violet for quantification ( n = 3 biologically independent experiments). Scale bar, 100 μm. Error bars represent s.d. Statistical significance was assessed using a two-sided unpaired Wilcoxon rank-sum test. e Re-expression of <t>shRNA-resistant</t> wild-type EIF6 using pCDH <t>lentivirus</t> restores HGF-induced cell attachment in EIF6 knockdown cells. Top: immunoblot showing EIF6 knockdown and re-expression efficiency. Bottom, quantification of crystal violet–stained colonies ( n = 4 independent experiments). Error bars represent s.d. Statistical significance was assessed using a two-sided unpaired Wilcoxon rank-sum test. f Representative images of H69 cells with EIF6 knockdown and re-expression after HGF treatment (40 ng mL⁻¹) for three weeks. Bright-field images (left) and crystal violet–stained colonies (right) are shown. Scale bar, 20 μm. g Live/dead cell analysis of shNTC and shEIF6 H69M cells treated with or without EP (carboplatin 10 μM and etoposide 2 μM) for 72 h, measured by flow cytometry. Data are mean ± SEM from n = 3 independent experiments. Statistical significance was determined using a two-sided unpaired Wilcoxon rank-sum test. h Chemotherapy sensitivity of subcutaneous xenografts derived from shNTC or shEIF6 H69 cells. Tumour volume changes were assessed after three chemotherapy cycles ( n = 13 tumours per group). Response categories were defined as CR (−100%), PR (−30% to 0%) and PD (>20%). Lowercase letters indicate tumours used for immunohistochemistry in i . Created in BioRender. Shen, S. (2026) https://BioRender.com/5p1ea8h . i Representative immunohistochemistry images of ASCL1, NEUROD1, POU2F3, YAP1 and EIF6 in corresponding tumours from h . Scale bars, 50 μm.
    Plko 1 Shrna Plasmids, supplied by Addgene inc, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/shrna+plasmid+with+pspax2/pm41066234-302-1-7?v=Addgene+inc
    Average 98 stars, based on 1 article reviews
    plko 1 shrna plasmids - by Bioz Stars, 2026-07
    98/100 stars
      Buy from Supplier

    Image Search Results


    a Enrichment of EMT and NE gene signatures following EIF6 knockdown in non-NE cell states. RNA-seq analysis is performed in n = 2 biologically independent samples. b Gene expression profiling of EMT- and NE-associated pathways upon EIF6 knockdown in non-NE cell states. RNA-seq analysis is performed in n = 2 biologically independent samples. c Immunoblot analysis of EMT-associated and NE proteins following EIF6 knockdown across multiple SCLC models. Blots are representative of n = 3 biologically independent experiments. For H69M, the samples derive from the same experiment but different gels for ZEB1, another for ZEB2, another for MYCN, another for YAP1, another for eIF6 and c-Myc, another for ASCL1, NEUROD1 and β-tubulin were processed in parallel; For H82R, the samples derive from the same experiment but different gels for ZEB2, ZEB1, MYCN and c-Myc, another for YAP1 and ASCL1, another for NEUROD1, eIF6 and β-tubulin were processed in parallel. For H209A, the samples derive from the same experiment, but different gels for ZEB2, ZEB1, MYCN and c-Myc, another for YAP1 and ASCL1, another for eIF6, another for NEUROD1 and β-tubulin were processed in parallel. d H69 cells with EIF6 knockdown were treated with HGF (40 ng mL⁻¹) for two weeks. Bright-field images show adherent growth (top). Attached colonies were stained with crystal violet for quantification ( n = 3 biologically independent experiments). Scale bar, 100 μm. Error bars represent s.d. Statistical significance was assessed using a two-sided unpaired Wilcoxon rank-sum test. e Re-expression of shRNA-resistant wild-type EIF6 using pCDH lentivirus restores HGF-induced cell attachment in EIF6 knockdown cells. Top: immunoblot showing EIF6 knockdown and re-expression efficiency. Bottom, quantification of crystal violet–stained colonies ( n = 4 independent experiments). Error bars represent s.d. Statistical significance was assessed using a two-sided unpaired Wilcoxon rank-sum test. f Representative images of H69 cells with EIF6 knockdown and re-expression after HGF treatment (40 ng mL⁻¹) for three weeks. Bright-field images (left) and crystal violet–stained colonies (right) are shown. Scale bar, 20 μm. g Live/dead cell analysis of shNTC and shEIF6 H69M cells treated with or without EP (carboplatin 10 μM and etoposide 2 μM) for 72 h, measured by flow cytometry. Data are mean ± SEM from n = 3 independent experiments. Statistical significance was determined using a two-sided unpaired Wilcoxon rank-sum test. h Chemotherapy sensitivity of subcutaneous xenografts derived from shNTC or shEIF6 H69 cells. Tumour volume changes were assessed after three chemotherapy cycles ( n = 13 tumours per group). Response categories were defined as CR (−100%), PR (−30% to 0%) and PD (>20%). Lowercase letters indicate tumours used for immunohistochemistry in i . Created in BioRender. Shen, S. (2026) https://BioRender.com/5p1ea8h . i Representative immunohistochemistry images of ASCL1, NEUROD1, POU2F3, YAP1 and EIF6 in corresponding tumours from h . Scale bars, 50 μm.

    Journal: Nature Communications

    Article Title: Eukaryote initiation factor 6 modulates small-cell lung carcinoma plasticity via the integrin-FAK signaling axis

    doi: 10.1038/s41467-026-69899-8

    Figure Lengend Snippet: a Enrichment of EMT and NE gene signatures following EIF6 knockdown in non-NE cell states. RNA-seq analysis is performed in n = 2 biologically independent samples. b Gene expression profiling of EMT- and NE-associated pathways upon EIF6 knockdown in non-NE cell states. RNA-seq analysis is performed in n = 2 biologically independent samples. c Immunoblot analysis of EMT-associated and NE proteins following EIF6 knockdown across multiple SCLC models. Blots are representative of n = 3 biologically independent experiments. For H69M, the samples derive from the same experiment but different gels for ZEB1, another for ZEB2, another for MYCN, another for YAP1, another for eIF6 and c-Myc, another for ASCL1, NEUROD1 and β-tubulin were processed in parallel; For H82R, the samples derive from the same experiment but different gels for ZEB2, ZEB1, MYCN and c-Myc, another for YAP1 and ASCL1, another for NEUROD1, eIF6 and β-tubulin were processed in parallel. For H209A, the samples derive from the same experiment, but different gels for ZEB2, ZEB1, MYCN and c-Myc, another for YAP1 and ASCL1, another for eIF6, another for NEUROD1 and β-tubulin were processed in parallel. d H69 cells with EIF6 knockdown were treated with HGF (40 ng mL⁻¹) for two weeks. Bright-field images show adherent growth (top). Attached colonies were stained with crystal violet for quantification ( n = 3 biologically independent experiments). Scale bar, 100 μm. Error bars represent s.d. Statistical significance was assessed using a two-sided unpaired Wilcoxon rank-sum test. e Re-expression of shRNA-resistant wild-type EIF6 using pCDH lentivirus restores HGF-induced cell attachment in EIF6 knockdown cells. Top: immunoblot showing EIF6 knockdown and re-expression efficiency. Bottom, quantification of crystal violet–stained colonies ( n = 4 independent experiments). Error bars represent s.d. Statistical significance was assessed using a two-sided unpaired Wilcoxon rank-sum test. f Representative images of H69 cells with EIF6 knockdown and re-expression after HGF treatment (40 ng mL⁻¹) for three weeks. Bright-field images (left) and crystal violet–stained colonies (right) are shown. Scale bar, 20 μm. g Live/dead cell analysis of shNTC and shEIF6 H69M cells treated with or without EP (carboplatin 10 μM and etoposide 2 μM) for 72 h, measured by flow cytometry. Data are mean ± SEM from n = 3 independent experiments. Statistical significance was determined using a two-sided unpaired Wilcoxon rank-sum test. h Chemotherapy sensitivity of subcutaneous xenografts derived from shNTC or shEIF6 H69 cells. Tumour volume changes were assessed after three chemotherapy cycles ( n = 13 tumours per group). Response categories were defined as CR (−100%), PR (−30% to 0%) and PD (>20%). Lowercase letters indicate tumours used for immunohistochemistry in i . Created in BioRender. Shen, S. (2026) https://BioRender.com/5p1ea8h . i Representative immunohistochemistry images of ASCL1, NEUROD1, POU2F3, YAP1 and EIF6 in corresponding tumours from h . Scale bars, 50 μm.

    Article Snippet: Lentiviruses were made by co-transfection of the shRNA lentivirus vector and the packaging plasmid psPAX2 (addgene#12260) and pMD2.G (addgene#12259) through calcium phosphate co-precipitation into 293 T cells.

    Techniques: Knockdown, RNA Sequencing, Gene Expression, Western Blot, Staining, Expressing, shRNA, Cell Attachment Assay, Cell Analysis, Flow Cytometry, Derivative Assay, Immunohistochemistry